13TH INTERNATIONAL PROSTATE CANCER UPDATE

The 13th International Prostate Cancer Update was held in Vail, Colorado, in February 2003. This article provides an overview of the high points in the areas of complementary medicine, chemoprevention, and staging that were discussed at this meeting. M. Scott Lucia, MD, addressed the use of various hormonal agents, antiproliferative or differentiating agents, antiinflammatory agents, and antioxidants in patients with prostate cancer. Wael A. Sakr, MD, provided an overview of prognostic markers for this disease. Arturo Mendoza-Valdes, MD, explored the potential role of exercise for patients with prostate cancer, and Bruce Sodee, MD, described some exciting new developments in prostate imaging. E. David Crawford, MD, discussed the ongoing Prostate Cancer Prevention Trial. [Rev Urol. 2003;5(suppl 6):S23-S32]

[1]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Egorin,et al.  Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Walsh.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2003, The Journal of urology.

[4]  P. Walsh.  Quality of life after radical prostatectomy or watchful waiting. , 2003, The Journal of urology.

[5]  A. Berg.  Screening for prostate cancer: recommendations and rationale. , 2003, The American journal of nursing.

[6]  C. Higano.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. , 2003, Urology.

[7]  E. Crawford.  Early versus late hormonal therapy: debating the issues. , 2003, Urology.

[8]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[9]  T. Wilt,et al.  Informing patients about prostate cancer screening: identifying and meeting the challenges while the evidence remains uncertain. , 2002, American Journal of Medicine.

[10]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[11]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[12]  David Verbel,et al.  Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. , 2002, Urology.

[13]  P. Troncoso,et al.  Role of systematic ultrasound‐guided staging biopsies in predicting extraprostatic extension and seminal vesicle invasion in men with prostate cancer , 2002, Journal of clinical ultrasound : JCU.

[14]  E. Messing,et al.  Timing hormonal therapy in prostate cancer. , 2002, The Urologic clinics of North America.

[15]  Joseph A. Smith,et al.  Informed choice in cancer screening. , 2002, The Journal of urology.

[16]  I. Eltoum,et al.  Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). , 2001, Cancer research.

[17]  J. Schalken,et al.  Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis , 2001, BJU international.

[18]  T. Beer,et al.  Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Levine,et al.  The role of cyclooxygenase-2 in prostate cancer. , 2001, Urology.

[20]  S Beddar,et al.  Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. , 2001, International journal of radiation oncology, biology, physics.

[21]  G. Wilding,et al.  Prostate cancer prevention strategies using antiproliferative or differentiating agents. , 2001, Urology.

[22]  C. Friedenreich,et al.  Physical activity and cancer prevention: from observational to intervention research. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  M. Carducci,et al.  Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors , 2000, Expert opinion on investigational drugs.

[24]  G. Bakale,et al.  Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. , 2000, Urology.

[25]  B. Redman,et al.  Weekly 1‐hour infusion of paclitaxel , 2000, Cancer.

[26]  M E Hammond,et al.  Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. , 2000, Archives of pathology & laboratory medicine.

[27]  V. Reuter,et al.  Prostate-specific membrane antigen: present and future applications. , 2000, Urology.

[28]  M. Rubin,et al.  Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. , 2000, The American journal of surgical pathology.

[29]  M. Cuendet,et al.  The Role of Cyclooxygenase and Lipoxygenase in Cancer Chemoprevention , 2000, Drug metabolism and drug interactions.

[30]  J. Picus,et al.  Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. , 1999, Seminars in oncology.

[31]  G. Blackburn,et al.  Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. , 1999, The Journal of nutrition.

[32]  J. Mohler,et al.  Evaluation of Biomarker Modulation by Fenretinide in Prostate Cancer Patients , 1999, European Urology.

[33]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[34]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[35]  W. Murphy.  ASAP is a bad idea. Atypical small acinar proliferation. , 1999, Human pathology.

[36]  I Mehdi,et al.  Early detection of prostate cancer. , 1998, JPMA. The Journal of the Pakistan Medical Association.

[37]  M. Gleave,et al.  Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience , 1998, European Urology.

[38]  N. Neff,et al.  Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  J. Oesterling,et al.  Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. , 1998, The American journal of medicine.

[40]  A. Partin,et al.  Ability of sextant biopsies to predict radical prostatectomy stage. , 1998, Urology.

[41]  D. Ransohoff,et al.  Early detection of prostate cancer. Serendipity strikes again. , 1997, JAMA.

[42]  J. Isaacs,et al.  Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin , 1997, The Prostate.

[43]  J. Oesterling,et al.  Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. , 1997, The Urologic clinics of North America.

[44]  E. Crawford,et al.  Proposed substages for metastatic prostate cancer. , 1997, Urology.

[45]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[46]  S. N. Lima,et al.  Community health : education and promotion manual , 1996 .

[47]  M. Anver,et al.  Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. , 1995, Cancer research.

[48]  J. Crowley,et al.  Design of the Prostate Cancer Prevention Trial (PCPT). , 1995, Controlled clinical trials.

[49]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[50]  D. Bostwick,et al.  Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. , 1994, The American journal of surgical pathology.

[51]  B. Yeap,et al.  Taxol in advanced, hormone‐refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group , 1993, Cancer.

[52]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[53]  M. F. Etreby,et al.  Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies. , 1991, Journal of andrology.

[54]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[55]  T. Stamey,et al.  Zonal Distribution of Prostatic Adenocarcinoma: Correlation with Histologic Pattern and Direction of Spread , 1988, The American journal of surgical pathology.

[56]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[57]  R. E. Peterson,et al.  Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. , 1975, Science.

[58]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.